EP-104IAR ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 1 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 172 / Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05608681 (ClinicalTrials.gov) | January 2023 | 19/10/2022 | A Trial Evaluating EP-104IAR in Adults With Eosinophilic Esophagitis | A Phase 1b, Open Label Trial Evaluating the Safety, Pharmacokinetics, and Efficacy of EP-104IAR in Adults With Eosinophilic Esophagitis (EoE) | Eosinophilic Esophagitis | Drug: EP-104IAR | Eupraxia Pharmaceuticals Inc. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 24 | Phase 1 | NULL |